Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $7.6667.

Several research analysts have weighed in on the company. Guggenheim reaffirmed a “buy” rating and set a $14.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Tuesday, April 21st. William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 31st.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $1.85 on Friday. The firm has a market capitalization of $342.78 million, a price-to-earnings ratio of -1.39 and a beta of 3.02. Neumora Therapeutics has a twelve month low of $0.66 and a twelve month high of $3.65. The stock’s 50 day moving average price is $2.20 and its two-hundred day moving average price is $2.35. The company has a quick ratio of 5.09, a current ratio of 5.09 and a debt-to-equity ratio of 0.75.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.02. Equities research analysts expect that Neumora Therapeutics will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NMRA. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in shares of Neumora Therapeutics during the 3rd quarter worth approximately $31,000. Legacy Private Trust Co. boosted its stake in shares of Neumora Therapeutics by 35.7% during the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares during the period. Fred Alger Management LLC bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $40,000. Finally, Canada Pension Plan Investment Board bought a new stake in Neumora Therapeutics in the 2nd quarter valued at $41,000. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.